Revolutionizing Retinal Health: Evoq's New Twilight Device
Evoq Technologies is set to transform retinal health monitoring with the launch of its FDA-registered device known as Twilight. This innovative technology, classified as a Class I medical device, is designed to detect retinal diseases like age-related macular degeneration (AMD) and inherited retinal diseases (IRDs) earlier than ever before. Founded in 2021, Evoq is focused on developing accessible diagnostics to ensure that critical conditions are caught before significant vision loss occurs.
How Twilight Works: The Features That Matter
The Twilight Dark Adaptometer enables patients to assess their retinal health from the comfort of their homes. Designed as a smartphone-based portable device, it allows for efficient measurement of how well the retina recovers from bright exposures to darkness—a crucial factor for monitoring retinal health. Components such as a handheld console, photostimulator headset, and an intuitive interface equipped with audio guidance, make the device user-friendly. Its design ensures ease of use not only in clinical environments but also permits at-home engagement, allowing patients to track their visual function independently.
Bridging the Gap: From Clinic to Home Monitoring
The accessibility of the Twilight device reflects a growing trend towards patient-driven healthcare. Professionals can gain real-time insights into their patients’ visual health through secure cloud storage and algorithm-driven data analysis, enabling them to keep track of changes over time efficiently. With a CPT code available for reimbursement under CPT 92284, it provides a financial incentive for clinics to adopt this cutting-edge technology, ensuring patients receive timely assessments long before more invasive options become necessary.
The Future of Eye Care: Early Detection is Key
Evoq’s mission aligns perfectly with the growing emphasis on early detection as a means to enhance patient outcomes. With conditions like AMD affecting millions, the Twilight device stands out by challenging traditional methods and streamlining diagnostic processes without requiring specialized environments or complicated workflows in clinics. As Daniel Lindgren, CEO of Evoq, states, 'Twilight fundamentally changes the diagnostic standard of care by revealing visual dysfunction years earlier.'
For further information about Evoq Technologies and the Twilight device, reach out to discover the game-changing potential it has for your clinical practice. Being informed about the latest advancements in retinal diagnostics can significantly impact patient care.
Add Row
Add
Write A Comment